Prestige Consumer Healthcare In (PBH) Stock Analysis
Falling Knife setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $47.20 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (4); Weak growth.
Prestige Consumer Healthcare develops and markets branded OTC health and personal care products (Monistat, Clear Eyes, Fleet, Dramamine, Summer's Eve, etc.) in North America and internationally, with 84.4% of revenues from the North American OTC segment in FY2025. Revenue comes... Read more
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $47.20 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (4); Weak growth. Chart setup: Death cross, below all MAs, RSI 20, MACD bearish. Score 5.2/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Prestige Consumer Healthcare In
Latest news
- Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance — Yahoo Finance neutral
- Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot - KING5.com — KING5.com neutral
- Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot - kare11.com — kare11.com neutral
- Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot - WKYC — WKYC neutral
- Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot - KTVB — KTVB neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Revenue shrinking — -5.0% YoY. Growth thesis broken unless recovery story develops.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.8/10 is below the 5.0 floor at $47.20 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (4); Weak growth. Chart setup: Death cross, below all MAs, RSI 20, MACD bearish. Prior stop was $43.89. Score 5.2/10, moderate confidence.
Take-profit target: $60.55 (+28.3% upside). Prior stop was $43.89. Stop-loss: $43.89.
Consecutive earnings misses (4); Weak growth; Negative momentum.
Prestige Consumer Healthcare In trades at a P/E of 12.0 (forward 9.6). TrendMatrix value score: 7.8/10. Verdict: Sell.
10 analysts cover PBH with a consensus score of 4.2/5. Average price target: $70.
What does Prestige Consumer Healthcare In do?Prestige Consumer Healthcare develops and markets branded OTC health and personal care products (Monistat, Clear Eyes,...
Prestige Consumer Healthcare develops and markets branded OTC health and personal care products (Monistat, Clear Eyes, Fleet, Dramamine, Summer's Eve, etc.) in North America and internationally, with 84.4% of revenues from the North American OTC segment in FY2025. Revenue comes from sales to mass merchandisers, drug, food, and e-commerce channels; Walmart and Amazon are the two largest customers.